February 11th marks International Day of Women and Girls in science, the purpose of which is to promote the ‘full and equal access and participation of females in STEM’.
According to United Nations, “Gender equality, besides being a fundamental human right, is essential to achieve peaceful societies, with full human potential and sustainable development.”
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
The next SysMIC Module 1 Course will start on Monday 24th April 2023.
The SysMIC course is run online from University College London and enables bioscience researchers to access an extended programme of training in coding, modelling and data analysis techniques.
Participants will become confident in using the Python, R and MATLAB platforms, developing interdisciplinary skills that will make them more effective researchers with the confidence to develop and apply computational techniques in modelling and data analysis to their own work.
Why SysMIC
Oversubscribed round led by Foresite Capital
Funding will enable development of DNA synthesis chip technology to commercial scale
We are today pleased to share the annual trading update for Bruntwood SciTech for 2022, which includes an overview of the £91m capital investment we confirmed last year. Very positively, it is our best performing year since forming in a partnership between Bruntwood and Legal & General in 2018, and we have and will continue to display an unwavering commitment to further cement the UK's position as an R&D powerhouse this year and beyond.
View the results via the links below.
Apply for the Primer Fund
Are you developing a solution to accelerate the diagnosis of MND? We're seeking proposals for funding in the areas of point of care diagnostic markers, digital markers of early symptoms and algorithmic approaches applied to pt data to detect changes indicative of MND. Proposals welcome from academia and industry. Deadline 20th Feb.
York, UK (January 31, 2023) – Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces a new partnership with BaseCure Therapeutics for the development of Optimer-targeted gene therapies. The ability to precisely target gene therapies, like siRNA-based therapeutics, to specific cells and tissues using Optimers offers exciting new opportunities for the field of gene therapy.
Become a mentor for a rare disease patient group leader who needs YOU and your skills!
This is your chance to give something back to a community that has given so much to those living with a rare disease.